Under pressure from neutralising antibodies induced by vaccination or infection the SARS-
CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all …

SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding
domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective …

Objectives Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to
vaccine-induced humoral immunity and the near complete loss of protective efficacy of …

Abstract Since> 3 years, SARS-CoV-2 has plunged humans into a colossal pandemic.
Henceforth, multiple waves of infection have swept through the human population, led by …

In vaccine development, many use the spike protein (S protein), which has multiple “spike-
like” structures protruding from the spherical structure of the coronavirus, as an antigen …

The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the
effectiveness of antibody therapeutics necessitates development of next-generation …

Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 receptor-binding domain (RBD)
showed high efficacy in the prevention and treatment of COVID-19. However, the rapid …

The recently dominant SARS-CoV-2 Omicron JN. 1 has evolved into multiple sublineages,
with recurrent spike mutations R346T, F456L, and T572I, some of which exhibit growth …

BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-
oxopiperidin-3-yl] ethyl] amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide …

The invention provides, in various embodiments, polypeptides (eg, camelid antibodies and
antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe …